Global CRO Charles River Laboratories has signed a binding offer to acquire Citoxlab for approximately $510 million with the expected close during Q2 2019. Citoxlab is a non-clinical CRO specializing in regulated safety assessment services, non-regulated discovery services, and medical device testing. The acquisition will further strengthen Charles River’s position as a global early-stage CRO by expanding its scientific portfolio and geographic footprint according to Contract Pharma.

Source: ContractPharma

Pin It on Pinterest